| abstract |
The present invention provides a compound for the treatment of hepatitis C in combination with one or more hepatitis C therapeutic agents such as caspase inhibitors, cyclophilin inhibitors, metabolic pathway inhibitors, interferons and the like. A compound exemplified by the following formula or a pharmaceutically acceptable salt thereof: HCV NS2 protease inhibitor, HCV NS3 / 4A protease inhibitor, HCV NS3 helicase inhibitor, HCV NS4B replication factor inhibitor, HCV NS5B polymerase inhibitor, HCV entry inhibitor, HCV internal ribosome entry site inhibitor, One or more additional hepatitis C therapeutic agents selected from microsomal triglyceride transport protein inhibitors, α-glucosidase inhibitors, caspase inhibitors, cyclophilin inhibitors, immune modulators, metabolic pathway inhibitors, interferons, and nucleoside analogs And a pharmaceutically acceptable excipient in combination. [Selection figure] None |